RG 6146

Drug Profile

RG 6146

Alternative Names: RG6146; RO 6870810; TEN 010

Latest Information Update: 28 Aug 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Tensha Therapeutics
  • Developer Roche
  • Class Antineoplastics; Small molecules
  • Mechanism of Action Bromodomain and extraterminal domain protein inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity Yes

Highest Development Phases

  • Phase I Acute myeloid leukaemia; Diffuse large B cell lymphoma; Multiple myeloma; Myelodysplastic syndromes; Solid tumours

Most Recent Events

  • 27 Sep 2017 Roche plans a phase I trial for Ovarian cancer and Breast cancer (Combination therapy, Late-stage disease) in USA and Denmark(NCT03292172)
  • 24 Aug 2017 Phase-I clinical trials in Diffuse large B cell lymphoma (Refractory metastatic disease, Second-line therapy or greater, Combination therapy) in USA (SC) (NCT03255096)
  • 26 Jun 2017 Phase-I clinical trials in Multiple myeloma (Late-stage disease, Combination therapy, In adults, In the elderly, Second-line therapy or greater) in USA, Australia (SC) (NCT03068351)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top